Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside (scientific article published on 01 November 1999)

In-vitro and in-vivo antimicrobial activities of a novel cephalosporin derivative, CP6162, possessing a dihydroxypyridone moiety at the C-3 side chain

Q43458228

Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone

Q43459102

Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration

Q44483617

A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides.

Q50509590

Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety.

Q50522237

Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin.

Q50579015

Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy.

Q54395876

Once-daily dosing decreases renal accumulation of gentamicin and netilmicin

Q69936275

Early effects of gentamicin, tobramycin, and amikacin on the human kidney

Q70624738

P433

issue

P921

main subject

pharmacodynamics

Q725307

P304

page(s)

1252-1260

P577

publication date

1999-11-01

P1433

published in

Pharmacotherapy

Q7180800

P1476

title

Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside

P478

volume

Reverse relations

cites work (P2860)

Q31075196	A Bayesian Modelling Approach with Balancing Informative Prior for Analysing Imbalanced Data
Q81721197	A case of an acute kidney injury secondary to an implanted aminoglycoside
Q41999444	Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations
Q48528055	Amikacin Pharmacokinetic-Pharmacodynamic (PK-PD) Analysis in Pediatric Cancer Patients
Q44436107	Aminoglycoside dosages and nephrotoxicity: quantitative relationships
Q34735262	Aminoglycoside nephrotoxicity: modeling, simulation, and control
Q38851189	Aminoglycosides: An Overview
Q35043373	Clinical issues surrounding once-daily aminoglycoside dosing in children
Q42549535	Comparative pharmacodynamics of gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa
Q44041308	Efficacy and tolerability of extended-interval aminoglycoside administration in pediatric patients.
Q36191093	Evaluation of serum concentrations achieved with an empiric once-daily tobramycin dosage regimen in children and adults with cystic fibrosis
Q35840780	Lack of effect of DX-619, a novel des-fluoro(6)-quinolone, on glomerular filtration rate measured by serum clearance of cold iohexol
Q30245399	Managing infective endocarditis in the elderly: new issues for an old disease.
Q42556968	Once versus individualized multiple daily dosing of aminoglycosides in critically ill patients
Q35738386	Once-daily aminoglycoside dosing: An update on current literature
Q35688447	Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases
Q61833608	Pharmacokinetic/pharmacodynamic antimicrobial individualization and optimization strategies
Q37956403	Pharmacological considerations for the proper clinical use of aminoglycosides
Q93609063	References
Q87393334	Section 3: Prevention and Treatment of AKI
Q87393341	Section 4: Contrast-induced AKI
Q39223551	Should aminoglycoside antibiotics be abandoned?

P356	DOI	10.1592/PHCO.19.16.1252.30876
P698	PubMed publication ID	10555931